- Home
- NXL vs CERO Comparison
NXL vs CERO Comparison
Compare NXL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- CERO
- Stock Information
- Founded
- NXL 2010
- CERO 2017
- Country
- NXL United States
- CERO United States
- Employees
- NXL N/A
- CERO N/A
- Industry
- NXL Medical Specialities
- CERO
- Sector
- NXL Health Care
- CERO
- Exchange
- NXL Nasdaq
- CERO Nasdaq
- Market Cap
- NXL 10.0M
- CERO 8.4M
- IPO Year
- NXL 2022
- CERO N/A
- Fundamental
- Price
- NXL $2.87
- CERO $1.79
- Analyst Decision
- NXL Hold
- CERO
- Analyst Count
- NXL 1
- CERO 0
- Target Price
- NXL N/A
- CERO N/A
- AVG Volume (30 Days)
- NXL 377.2K
- CERO 745.6K
- Earning Date
- NXL 03-26-2025
- CERO 03-04-2025
- Dividend Yield
- NXL N/A
- CERO N/A
- EPS Growth
- NXL N/A
- CERO N/A
- EPS
- NXL N/A
- CERO N/A
- Revenue
- NXL $162,078.00
- CERO N/A
- Revenue This Year
- NXL $56.86
- CERO N/A
- Revenue Next Year
- NXL $167.44
- CERO N/A
- P/E Ratio
- NXL N/A
- CERO N/A
- Revenue Growth
- NXL 26.00
- CERO N/A
- 52 Week Low
- NXL $0.30
- CERO $1.57
- 52 Week High
- NXL $4.49
- CERO $1,095.00
- Technical
- Relative Strength Index (RSI)
- NXL 42.81
- CERO 36.41
- Support Level
- NXL $2.80
- CERO $1.70
- Resistance Level
- NXL $3.54
- CERO $2.10
- Average True Range (ATR)
- NXL 0.38
- CERO 0.23
- MACD
- NXL -0.02
- CERO 0.23
- Stochastic Oscillator
- NXL 14.53
- CERO 33.85
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.